Suven Life - Press Release

Suven Life Sciences Ltd on December 11, 2007 has announced that Mr. Venkat Jasti, Vice Chairman and CEO will present Suven's Drug Discovery Pipeline at Windhover's Bio / Partnerships conference in San Francisco on December 13th. Windhover's Bio / Pharma Partnerships, is an exclusive partnering conference that links global biotechnology and pharmaceutical Companies to explore potential Collaborations, M&A, Alliances and financing activities.

The conference provide platform for the most promising innovator Companies to present their Companies which are handpicked by Windhover's Information Inc. In addition to presenting at this conference, Suven will be holding one-to-one meeting with various senior-level dealmakers for collaborations, Financing initiatives and alliances.

Suven has been working on innovative technology platforms particularly in the class of selective 5-HT compounds for development as therapeutic agents in the treatment of neuro-degenerative disorders like Alzheimer's Alltention deficient hyperactivity, Hyntington's, Parkinson and Schizophrenia and Obesity.

Suven thus far has filled 26 products patents under PCT out of which 10 has entered national phase. So far 36 products patents were granted from 12 countries. Suven has already filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of Suven.

Suven since September-2006 is also working as a collaborative Research Partner (CRP) with Elli Lilly to Discover and Develop NCEs for an unmet medical need in CNS therapeutic area.

Suven is a major service provider of Drug Discovery and Development support Services (DDDSS) to global Pharmaceutical, Life Sciences and Biotech Companies in addition to their continued business interest and growth in Contract Research and Manufacturing Services (CRAMS).